This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, X. J. Articles by Wolf, C. R. Search for Related Content PubMed PubMed Citation Articles by Wang, X. J. Articles by Wolf, C. R.

Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

¹ Cancer Research UK Molecular Pharmacology Unit and ² Biomedical Research Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom

Requests for reprints: C. Roland Wolf, Cancer Research UK Molecular Pharmacology Unit, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, Scotland, United Kingdom. Phone: 44-1382-632621; Fax: 44-1382-669993; E-mail: roland.wolf{at}cancer.org.uk.

The NF-E2 p45-related factor 2 (Nrf2) regulates cytoprotective genes that contain an antioxidant response element (ARE) in their promoters. To investigate whether anticancer drugs can induce ARE-driven gene expression, we have developed a stable human mammary MCF7-derived reporter cell line called AREc32, which contains a luciferase gene construct controlled by eight copies of the cis-element. In these cells, luciferase activity was increased up to 50-fold following treatment with 50 µmol/L tert-butylhydroquinone (t-BHQ). Basal and inducible luciferase activities in AREc32 cells were increased by forced overexpression of Nrf2 and reduced by knockdown of endogenous Nrf2 expression with RNA interference. Depletion of cellular reduced glutathione (GSH) by treatment of AREc32 cells with L-buthionine-S,R-sulfoximine (BSO) did not influence basal levels of luciferase activity, but pretreatment with BSO augmented induction of luciferase activity by t-BHQ. Induction of reporter activity by t-BHQ in AREc32 cells was suppressed markedly by the antioxidants N-acetylcysteine and GSH but only modestly by vitamins C or E, suggesting that ARE-luciferase expression is induced primarily by thiol-active electrophiles rather than free radicals. The anticancer drugs cisplatin, etoposide, mitoxantrone, chlorambucil, melphalan, and carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)] weakly induced luciferase activity in AREc32 cells. Moreover, treatment of AREc32 cells with BSO immediately before exposure to anticancer drugs enhanced induction of ARE-driven luciferase activity by cisplatin, BCNU, chlorambucil, and melphalan and also induced endogenous AKR1C (AKR1C refers to AKR1C1 and AKR1C2), a target gene of Nrf2. Our findings show that Nrf2 can be activated by certain anticancer agents, and this will influence the effectiveness of chemotherapy. (Cancer Res 2006; 66(22): 10983-94)

This article has been cited by other articles:

				A.K. MacLeod, M. McMahon, S. M. Plummer, L. G. Higgins, T. M. Penning, K. Igarashi, and J. D. Hayes Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds Carcinogenesis, September 1, 2009; 30(9): 1571 - 1580. [Abstract] [Full Text] [PDF]

				Y. Zhang, A. Kobayashi, M. Yamamoto, and J. D. Hayes The Nrf3 Transcription Factor Is a Membrane-bound Glycoprotein Targeted to the Endoplasmic Reticulum through Its N-terminal Homology Box 1 Sequence J. Biol. Chem., January 30, 2009; 284(5): 3195 - 3210. [Abstract] [Full Text] [PDF]

				Y. J. Cui, X. Cheng, Y. M. Weaver, and C. D. Klaassen Tissue Distribution, Gender-Divergent Expression, Ontogeny, and Chemical Induction of Multidrug Resistance Transporter Genes (Mdr1a, Mdr1b, Mdr2) in Mice Drug Metab. Dispos., January 1, 2009; 37(1): 203 - 210. [Abstract] [Full Text] [PDF]

				A. Natsch, R. Emter, and G. Ellis Filling the Concept with Data: Integrating Data from Different In Vitro and In Silico Assays on Skin Sensitizers to Explore the Battery Approach for Animal-Free Skin Sensitization Testing Toxicol. Sci., January 1, 2009; 107(1): 106 - 121. [Abstract] [Full Text] [PDF]

				X.-J. Wang, Z. Sun, N. F. Villeneuve, S. Zhang, F. Zhao, Y. Li, W. Chen, X. Yi, W. Zheng, G. T. Wondrak, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 Carcinogenesis, June 1, 2008; 29(6): 1235 - 1243. [Abstract] [Full Text] [PDF]

				A. Natsch and R. Emter Skin Sensitizers Induce Antioxidant Response Element Dependent Genes: Application to the In Vitro Testing of the Sensitization Potential of Chemicals Toxicol. Sci., March 1, 2008; 102(1): 110 - 119. [Abstract] [Full Text] [PDF]

				X. J. Wang, J. D. Hayes, C. J. Henderson, and C. R. Wolf Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha PNAS, December 4, 2007; 104(49): 19589 - 19594. [Abstract] [Full Text] [PDF]